Predictive Genetic Testing And Consumer Genomics Market Size, Share & Trends Report

Predictive Genetic Testing And Consumer Genomics Market Size, Share & Trends Analysis Report By Test Type (Population Screening, Susceptibility), By Application, By Setting Type, And Segment Forecasts, 2019 - 2025

  • Report ID: GVR-1-68038-374-4
  • Number of Pages: 220
  • Format: Electronic (PDF)
  • Historical Range: 2014 - 2017
  • Industry: Healthcare

Research Methodology

A three-pronged approach was followed for deducing the predictive genetic testing and consumer genomics market estimates and forecasts. The process has three steps: information procurement, analysis, and validation. The whole process is cyclical, and steps repeat until the estimates are validated. The three steps are explained in detail below:

Information procurement: Information procurement is one of the most extensive and important stages in our research process, and quality data is critical for accurate analysis. We followed a multi-channel data collection process for predictive genetic testing and consumer genomics market to gather the most reliable and current information possible.

  • We buy access to paid databases such as Hoover’s and Factiva for company financials, industry information, white papers, industry journals, SME journals, and more.
  • We tap into Grand View’s proprietary database of data points and insights from active and archived monitoring and reporting.
  • We conduct primary research with industry experts through questionnaires and one-on-one phone interviews.
  • We pull from reliable secondary sources such as white papers and government statistics, published by organizations like WHO, NGOs, World Bank, etc., Key Opinion Leaders (KoL) publications, company filings, investor documents, and more.
  • We purchase and review investor analyst reports, broker reports, academic commentary, government quotes, and wealth management publications for insightful third-party perspectives.

Analysis: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilized different methods of predictive genetic testing and consumer genomics market data depending on the type of information we’re trying to uncover in our research.

  • Market Research Efforts: Bottom-up Approach for estimating and forecasting demand size and opportunity, top-down Approach for new product forecasting and penetration, and combined approach of both Bottom-up and Top-down for full coverage analysis.

  • Value-Chain-Based Sizing & Forecasting: Supply-side estimates for understanding potential revenue through competitive benchmarking, forecasting, and penetration modeling.

  • Demand-side estimates for identifying parent and ancillary markets, segment modeling, and heuristic forecasting.

  • Qualitative Functional Deployment (QFD) Modelling for market share assessment.

Market formulation and validation: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilize different methods of data analysis depending on the type of information we’re trying to uncover in our research.

  • Market Formulation: This step involves the finalization of market numbers. This step on an internal level is designed to manage outputs from the Data Analysis step.

  • Data Normalization: The final market estimates and forecasts are then aligned and sent to industry experts, in-panel quality control managers for validation.

  • This step also entails the finalization of the report scope and data representation pattern.

  • Validation: The process entails multiple levels of validation. All these steps run in parallel, and the study is forwarded for publishing only if all three levels render validated results.

Predictive Genetic Testing And Consumer Genomics Market Categorization:

The predictive genetic testing and consumer genomics market was categorized into four segments, namely test type (Predictive Testing, Consumer Genomics, Wellness Genomics), application (Predictive Genetic Testing & Consumer Genomics), setting type (DTC, Professional), and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa).

Segment Market Methodology:

The predictive genetic testing and consumer genomics market was segmented into test type, application, setting type, and region. The demand at a segment level was deduced using a funnel method. Concepts like the TAM, SAM, SOM, etc., were put into practice to understand the demand. We at GVR deploy three methods to deduce market estimates and determine forecasts. These methods are explained below:

Market research approaches: Bottom-up

  • Demand estimation of each product across countries/regions summed up to from the total market.

  • Variable analysis for demand forecast.

  • Demand estimation via analyzing paid database, and company financials either via annual reports or paid database.

  • Primary interviews for data revalidation and insight collection.

Market research approaches: Top-down

  • Used extensively for new product forecasting or analyzing penetration levels.

  • Tool used invoice product flow and penetration models Use of regression multi-variant analysis for forecasting Involves extensive use of paid and public databases.

  • Primary interviews and vendor-based primary research for variable impact analysis.

Market research approaches: Combined

  • This is the most common method. We apply concepts from both the top-down and bottom-up approaches to arrive at a viable conclusion.

Regional Market Methodology:

The predictive genetic testing and consumer genomics market was analyzed at a regional level. The globe was divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, keeping in focus variables like consumption patterns, export-import regulations, consumer expectations, etc. These regions were further divided into eleven countries, namely, the U.S., Canada, Germany, the UK, Japan, China, Australia, India, Singapore, Brazil, South Africa.

All three above-mentioned market research methodologies were applied to arrive at regional-level conclusions. The regions were then summed up to form the global market.

Predictive genetic testing and consumer genomics market companies & financials:

The predictive genetic testing and consumer genomics market was analyzed via companies operating in the sector. Analyzing these companies and cross-referencing them to the demand equation helped us validate our assumptions and conclusions. Key market players analyzed include:

  • F. Hoffmann-La Roche Ltd  - F. Hoffmann-La Roche AG, a Basel-based company, is actively engaged in the creation and production of pharmaceutical and diagnostic products. The company operates 26 manufacturing facilities worldwide. It functions in two main sectors: pharmaceuticals and diagnostics. The pharmaceutical division produces medications for a variety of conditions, including infectious diseases, cardiovascular and respiratory conditions, cancer, metabolic disorders, diseases of the central nervous system, and autoimmune diseases. Roche Diagnostics participates in a wide range of market segments, from patient self-monitoring to clinical laboratory systems. Roche Professional Diagnostics (RPD), the company’s largest business unit, offers solutions, tests, and instrument systems to ensure the reliable and cost-effective delivery of results. Ventana Medical Systems, a Roche group member, is involved in the creation of assays and kits for InSyte hybridization techniques. The company has made several acquisitions, including GeneWEAVE Biosciences in the molecular diagnostics sector, Ariosa Diagnostics, Signature Diagnostics, CAPP Medical, and Kapa BioSystems in the sequencing business. In 2007, it also acquired 454 Life Sciences, which began operating as a Roche subsidiary. The company has a global presence, with operations in North America, South America, Europe, Africa, Asia, and Oceania.

  • Abbott (Abbott Diagnostics) - Abbott Diagnostics, a division of Abbott Laboratories, provides diagnostic solutions, including training programs and service products, for both healthcare professionals and patients. Their offerings encompass a wide range of products such as clinical products, automation, tests by conditions, and service products. They cater to various areas including point-of-care, diabetes care, and molecular diagnostics, providing clinical chemistry, immunoassay, blood screening, molecular, hematology, point-of-care, and informatics for in vitro diagnostics. Some of their well-known diagnostic brands are Architect, Abbott Prism, Accelerator A3600, Cell-Dyn, M2000, Iridica, and I-STAT. Abbott operates globally with branches in Africa, Asia, Europe, North America, South America, and the South Pacific. The company is divided into four main segments: diagnostic products, nutritional products, established pharmaceutical products, and vascular products.

  • Thermo Fisher Scientific, Inc. - Thermo Fisher Scientific, Inc., a publicly traded biotechnology firm, was formed because of the merger between Thermo Electron and Fisher Scientific. In 2013, it outbid F. Hoffmann-La Roche Ltd to acquire Life Technologies Corporation. The company offers a range of products in the fields of life science, industrial and applied science, and clinical diagnostics. With operations spread across 50 countries, Thermo Fisher markets its products under several brands including Applied Biosystems, Thermo Scientific, Fisher Scientific, Invitrogen, and Unity Lab Services. In March 2016, the company expanded its portfolio by acquiring Affymetrix, Inc.

  • Agilent Technologies - Agilent Technologies, a company based in the United States, specializes in supplying analytical instruments and software to analytical scientists and clinical researchers. The company operates in various sectors including pharmaceutical, food, chemical & energy, environmental & forensics, and research. It offers a range of products and services in its life science and applied market segment, including liquid & gas chromatography, mass spectrometry, spectroscopy, genomics & diagnostics consumables, services, and software. Agilent Technologies was established in 1999 as a spin-off from Hewlett-Packard. The company distributes its products through direct sales, resellers, distributors, e-commerce, and manufacturer’s representatives. It has a global presence with operations in the Americas, Europe, Africa, and the Asia Pacific regions. The company’s diagnostics and genomics business comprises companion diagnostics, nucleic acid contract manufacturing & pathology, genomics, and reagent partnership businesses. Its genomics portfolio includes genotyping, DNA methylation profiling, identification of gene rearrangements, gene expression profiling, gene copy number determination, arrays for DNA mutation detection, Next-generation sequencing (NGS) target enrichment, and genetic data management & interpretation support software.

  • BGI - BGI, also known as Beijing Genomics Institute, is a center for genome sequencing that was established with the main goal of representing China in the Human Genome Project. Despite being non-governmental in its administration, it serves as a representative of the Chinese government in genomic sequencing. In 2002, BGI achieved a milestone by sequencing the rice genome. The institute operates as a semi-private and semi-public entity, receiving funding from both the Chinese government and private investors. It has several subsidiaries including BGI Research, BGI Tech, BGI Diagnosis, BGI Manufacturing, and China National GeneBank. BGI has international subsidiaries such as BGI Americas in Cambridge, Massachusetts, and BGI Europe in Copenhagen. The company has a global presence with nine offices spread across five continents, including locations in Denmark, Cambridge, Hong Kong, China, and Japan. In March 2013, BGI expanded its operations by acquiring Complete Genomics. Its primary laboratories are situated in Copenhagen, Denmark; Philadelphia, USA; and Hong Kong, China.

  • Bio-Rad Laboratories, Inc. - Bio-Rad Laboratories, Inc., established in 1957, is a global provider of tools and services to various markets including life science research, food science, and clinical diagnostics. The company is instrumental in advancing scientific research and development by introducing new technologies in areas such as proteomics, genomics, food safety, medical diagnostics, drug discovery, and more. Bio-Rad operates through two main segments: life science and clinical diagnostics. The life science segment focuses on the development, manufacturing, and marketing of reagents, laboratory instruments, and apparatus used in clinical research and food testing, among others. On the other hand, the clinical diagnostics segment is responsible for the sale, manufacture, and support of test kits, test systems, specialized quality controls, and informatics systems catering to clinical laboratories in the diagnostics market. The company boasts a diverse product portfolio that includes reagents, instruments, and software for the in vitro diagnostics (IVD) test market, supplying over 300 clinical diagnostics tests for IVD use. Bio-Rad’s clinical diagnostics branches are spread across various locations including Hercules, Benicia, and Irvine in California; the greater Seattle area in Washington; Cambridge, Massachusetts; Lille and the greater Paris area in France; Nazareth-Eke, Belgium; Cressier, Switzerland; and Dreieich, Germany.

  • Illumina, Inc. - Illumina Inc. is primarily engaged in the creation, production, and distribution of comprehensive platforms and systems for sequencing. The company also participates in the examination and study of genomic and proteomic data, as well as the determination of a gene sequence’s biological function and expression. Illumina provides next-generation sequencing platforms for genotyping, sequencing, and gene expression analysis, and has a significant presence in the North American and European NGS markets. The company is committed to developing innovative sequencing technologies to reduce the cost of sequencing entire genomes. Illumina offers a range of genomic and molecular diagnostic products and services that serve various fields, including oncology, microbial genomics, drug development, agrigenomics, forensic genomics, infectious disease surveillance, molecular epidemiology, and translational research involving HLA sequencing and related applications.

  • QIAGEN - QIAGEN is a biotechnology company that is publicly traded. It has a global presence, operating in over 25 countries including the U.S., UK, Germany, Netherlands, France, and China. The company’s primary operations involve assay technologies for molecular diagnostics, pharmaceuticals, academia, and applied testing. QIAGEN offers a range of products in fields such as Next Generation Sequencing (NGS), molecular diagnostics, animal and veterinary testing, bioinformatics, food and safety testing, human identification and forensics, and life science research. QIAGEN collaborates with commercial partners and importers such as Tecnolab, UniMed Ltd, Global Pharmaceutical Solutions, and Suyog Diagnostics, among others. It also works with EVOTEC BioSystems AG and PreAnalytiX to provide assay solutions. In 2015, the company’s customer base and product sales for molecular diagnostics products made up 47% of net sales, an increase from 44% in 2014 and 39% in 2013.

  • Alere - Alere is a publicly traded company that specializes in delivering clinical data through quick diagnostic tests to improve healthcare outcomes both clinically and economically. The company, headquartered in Massachusetts, U.S., offers services in various fields including cardio metabolism, infectious diseases, toxicology, clinical immunology, oncology, and women’s health. Originally known as SelfCare, the company changed its name to Inverness Medical Technology (IMT) in 2000 and later to Alere in 2010. Alere has expanded its business by acquiring several companies such as Clondiag, TwistDx, Ostex International, Standard Diagnostics, Axis-Shield, Ionian Technologies, Wampole Laboratories, Binax, and Biosite. The company operates in various business segments including health information solutions, consumer diagnostics, and professional diagnostics. In February 2016, Abbott announced its intention to acquire Alere. However, in April 2016, Abbott expressed concerns about the accuracy of Alere’s financial information, which led to Abbott’s request to terminate the deal being rejected.

  • Myriad Genetics, Inc. - Myriad Genetics, Inc., a molecular diagnostics lab, is at the forefront of personalized medicine development. The company offers services that evaluate the risk of cancer development, the severity of the disease, and the effectiveness of chemotherapy. It provides a platform for testing hereditary cancer, prognostic medicine, personalized medicine, and companion diagnostics. Myriad’s diagnostic pipeline covers a wide range of diseases, including autoimmune diseases, diabetes, neuropsychiatry, and nephrology. Myriad RBM, a biomarker discovery platform, equips oncologists and physicians with multiplexed data for drug development and patient care. The company has set up sales offices in France, Germany, Spain, the United Kingdom, Switzerland, Australia, Italy, and Canada, and operates laboratories in Germany. It has distribution partnerships with various organizations in certain European, Latin American, Asian, Middle Eastern, and African countries. In February 2014, Myriad Genetics expanded its business in the inflammatory and autoimmune disease market by acquiring Crescendo Bioscience, Inc. for USD 270 million in cash. As a result of this acquisition, Myriad Genetics took over Crescendo’s business, including its VectraDA blood test for managing Rheumatoid Arthritis (RA).

Value chain-based sizing & forecasting

Supply Side Estimates

  • Company revenue estimation via referring to annual reports, investor presentations, and Hoover’s.

  • Segment revenue determination via variable analysis and penetration modeling.

  • Competitive benchmarking to identify market leaders and their collective revenue shares.

  • Forecasting via analyzing commercialization rates, pipelines, market initiatives, distribution networks, etc.

Demand side estimates

  • Identifying parent markets and ancillary markets

  • Segment penetration analysis to obtain pertinent

  • revenue/volume

  • Heuristic forecasting with the help of subject matter experts

  • Forecasting via variable analysis

Predictive Genetic Testing And Consumer Genomics Market Report Objectives:

  • Understanding market dynamics (in terms of drivers, restraints, & opportunities) in the countries.

  • Understanding trends & variables in the individual countries & their impact on growth and using analytical tools to provide high-level insights into the market dynamics and the associated growth pattern.

  • Understanding market estimates and forecasts (with the base year as 2018, historic information from 2014 to 2017, and forecast from 2019 to 2025). Regional estimates & forecasts for each category are available and are summed up to form the global market estimates.

Predictive Genetic Testing And Consumer Genomics Market Report Assumptions:

  • The report provides market value for the base year 2018 and a yearly forecast till 2025 in terms of revenue/volume or both. The market for each of the segment outlooks has been provided on region & country basis for the above-mentioned forecast period.

  • The key industry dynamics, major technological trends, and application markets are evaluated to understand their impact on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis.

  • We have used the bottom-up approach for market sizing, analyzing key regional markets, dynamics, & trends for various products and end-users. The total market has been estimated by integrating the country markets.

  • All market estimates and forecasts have been validated through primary interviews with the key industry participants.

  • Inflation has not been accounted for to estimate and forecast the market.

  • Numbers may not add up due to rounding off.

  • Europe consists of EU-8, Central & Eastern Europe, along with the Commonwealth of Independent States (CIS).

  • Asia Pacific includes South Asia, East Asia, Southeast Asia, and Oceania (Australia & New Zealand).

  • Latin America includes Central American countries and the South American continent

  • Middle East includes Western Asia (as assigned by the UN Statistics Division) and the African continent.

Primary Research

GVR strives to procure the latest and unique information for reports directly from industry experts, which gives it a competitive edge. Quality is of utmost importance to us, therefore every year we focus on increasing our experts’ panel. Primary interviews are one of the critical steps in identifying recent market trends and scenarios. This process enables us to justify and validate our market estimates and forecasts to our clients. With more than 8,000 reports in our database, we have connected with some key opinion leaders across various domains, including healthcare, technology, consumer goods, and the chemical sector. Our process starts with identifying the right platform for a particular type of report, i.e., emails, LinkedIn, seminars, or telephonic conversation, as every report is unique and requires a differentiated approach.

We send out questionnaires to different experts from various regions/ countries, which is dependent on the following factors:

  • Report/Market scope: If the market study is global, we send questionnaires to industry experts across various regions, including North America, Europe, Asia Pacific, Latin America, and MEA.

  • Market Penetration: If the market is driven by technological advancements, population density, disease prevalence, or other factors, we identify experts and send out questionnaires based on region or country dominance.

The time to start receiving responses from industry experts varies based on how niche or well-penetrated the market is. Our reports include a detailed chapter on the KoL opinion section, which helps our clients understand the perspective of experts already in the market space.

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

ISO

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon